Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors. - Wikidata - awgldk - TriplyDB

Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.

Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.

http://www.wikidata.org/entity/Q34073681

about

Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.Treatment, behavioral, and psychosocial components of cardiovascular disease risk among survivors of childhood and young adult cancer Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy.Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis.Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.Cardiotoxicity of anthracycline therapy: current perspectives Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial Treatment-related cardiotoxicity in survivors of childhood cancer.Dexrazoxane: a cardioprotectant for pediatric cancer patients receiving anthracyclines.Cardiac complications in childhood cancer survivors treated with anthracyclines.Late Cardiotoxicity: Issues for Childhood Cancer Survivors.Dexrazoxane improves cardiac autonomic function in epirubicin-treated breast cancer patients with type 2 diabetes.Cardioprotective effect of early dexrazoxane use in anthracycline treated pediatric patients.An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines.The impact of doxorubicin and dexrazoxane injection of prepubertal female rats on pregnancy outcome and cardiac function postpartum.Cardiac response to doxorubicin and dexrazoxane in intact and ovariectomized young female rats at rest and after swim training.Protecting the heart in cancer therapy

P2860

Q26742059-20A28D64-C72B-4C1A-B017-C2951A93AFFA Q28088408-B0C83E03-2980-48B9-A44B-D1EB79152AD5 Q35588736-2766EF83-AD19-44A4-9B39-C1839F165756 Q35849444-9B7A6B5E-B190-41F9-868C-A6A550125417 Q36568915-A995FF50-B432-4233-80EE-0C5F0D5B9A3F Q36845348-BB81F42F-C8B7-4102-A67E-4A9C70F75955 Q37129069-F70A559A-53AC-44D3-B530-FC164EBAE1B6 Q38156036-57B65583-AE01-43CF-838D-D3D44313A12D Q38264693-C20F1F34-952A-4A3D-B9C3-5BA16680ABBB Q38588167-174DB884-DD27-4755-9FBB-D25CA7CD2C8F Q38845457-A53FFE17-BC3C-410F-BE5D-B014D8ED5CE0 Q41483888-5D5C376A-6E94-427B-9A18-61F54AD12AD2 Q45869428-111D3818-E6E2-4EF7-BCAB-57F66B7A847A Q48357803-1F408BBD-4FB8-4EC6-99BD-9B31C7F2AFA8 Q51294069-755BA88C-CBDF-4777-81FC-77474FEF0735 Q51350978-104623CE-BEF5-492C-81F6-B78F4E896169 Q57821006-8F359011-46ED-481B-82E0-FCC9B38BAF48

P2860

Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.

http://www.wikidata.org/entity/Q34073681

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.

@ast

Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.

@en

Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.

@nl

type

label

Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.

@ast

Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.

@en

Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.

@nl

prefLabel

Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.

@ast

Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.

@en

Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.

@nl

P1433

Q34073681-9A2F65A9-B4CA-4868-9D0E-4BC52F4B4252

P1476

Q34073681-C2100B06-BEFB-4FFA-A4C6-22DF4734DDBA

P2093

Q34073681-0C20E876-6657-4F45-BBBC-83B33CF17F17

Q34073681-278177E3-1250-41D8-8811-C98D2A7E3B47

Q34073681-2E82BD4D-C487-4CFD-8797-D45E108AFC39

Q34073681-47B1D494-382A-411F-AB26-C2EF02DEDD39

Q34073681-58B55B15-3381-4209-AA15-3ADAB5A47EB6

Q34073681-74E19BAF-16FF-4EC8-A7CE-0BDED4A652F7

Q34073681-C1440418-968D-4A98-8533-A3E5A63BC69E

Q34073681-FD27B30A-DAE9-434E-9059-724BFF0DF1A2

P2860

Q34073681-1CEC6E5A-C8C6-44BE-9FF9-A7ADC53A52D0

Q34073681-22E74E26-4346-4059-AE5A-EEE3A5E867A8

Q34073681-2AACAA95-6381-40C4-9855-46A22236C98F

Q34073681-2C9713CB-9EEF-4760-8EE7-5AE33F456F15

Q34073681-39F2B290-9282-4639-9391-E7A90D0D294D

Q34073681-3F71FD63-8639-4DC5-BF89-82B3A57C62E0

Q34073681-4C0DD1A3-65E9-42B4-AC64-3453A14536E4

Q34073681-5365CCBA-805C-4FDD-9B7A-04CD1DE3531B

Q34073681-61B69D81-4228-47EA-AB2B-17D3738A77CE

Q34073681-6DC2E03F-02AB-42BF-81CF-54E16BD643E7

P304

Q34073681-7DA7DD78-4B3A-4D56-A4C5-F77B0B9F664F

P31

Q34073681-F7B4A8AF-34F6-48AE-ADC8-0420C1BAD4D5

P356

Q34073681-8F536250-4525-496C-96B0-07ADE760A7BD

P433

Q34073681-A0FD734E-28B8-4535-9A91-8E5BAD0AA88C

P478

Q34073681-94B0E522-26B8-46FE-A4BE-FB6A08FD5D27

P577

Q34073681-D48BDE40-3DF4-4018-ACEC-C7D967E5C0AB

P5875

Q34073681-23C54516-AFF5-43E9-A009-C24AF01D3C71

P698

Q34073681-108FD1B0-463B-4A35-A65B-9E94D3E0CF42

P932

Q34073681-58FC9397-49EA-455E-BBCC-9250225E9CB3

P356

JKMS.2010.25.9.1336

P1433

Journal of Korean Medical Science

P1476

Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.

@en

P2093

Chung Il Noh

http://www.w3.org/2001/XMLSchema#string

Eun Sil Park

http://www.w3.org/2001/XMLSchema#string

Hee Young Shin

http://www.w3.org/2001/XMLSchema#string

Hyo Seop Ahn

http://www.w3.org/2001/XMLSchema#string

Hyoung Jin Kang

http://www.w3.org/2001/XMLSchema#string

Hyoung Soo Choi

http://www.w3.org/2001/XMLSchema#string

Jung Yun Choi

http://www.w3.org/2001/XMLSchema#string

Yong Soo Yun

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer

Cardioprotective interventions for cancer patients receiving anthracyclines

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia

Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.

American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.

Detection of anthracycline-induced cardiotoxicity.

Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review.

Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.

Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.

Prevention of anthracycline-induced cardiotoxicity in children: the evidence.

P304

1336-1342

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3346/JKMS.2010.25.9.1336

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46108425

http://www.w3.org/2001/XMLSchema#string

P698

20808678

http://www.w3.org/2001/XMLSchema#string

P932

2923785

http://www.w3.org/2001/XMLSchema#string